|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||
| 化学式 | C19H17ClN2O5 |
||||||
| 分子量 | 388.80 | CAS No. | 747413-08-7 | ||||
| Solubility (25°C)* | 体外 | DMSO | 77 mg/mL (198.04 mM) | ||||
| Ethanol | 77 mg/mL (198.04 mM) | ||||||
| Water | Insoluble | ||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||
| 製品説明 | VER-50589 is a potent HSP90 inhibitor with IC50 of 21 nM for HSP90β. |
|---|---|
| in vitro | VER-50589 inhibits the intrinsic ATPase activity of recombinant yeast Hsp90 with IC50 of 143 nM, and produces antiproliferative activity in a panel of human cancer cell lines and nontumorigenic cells in vitro. This compound causes induction of HSP72 and HSP27 alongside depletion of client proteins, including C-RAF, B-RAF, and survivin, and the protein arginine methyltransferase PRMT5, which further result in cell cycle arrest and apoptosis. [1] |
| in vivo | In HCT116 human colon cancer xenografts, VER-50589 (100 mg/kg i.p.) results in a statistically significant reduction of ∼30% in tumor volume and weight, as well as induction of HSP72 and depletion of ERBB2 and C-RAF. [1] |
| キナーゼアッセイ | Fluorescence Polarization Assay | |
|---|---|---|
| Binding of HSP90 inhibitors to human full-length recombinant HSP90β is determined by a competitive binding fluorescence polarization assay, using a fluorescent pyrazole resorcinol probe. | ||
| 細胞アッセイ | 細胞株 | Melanoma cells (SKMEL 2, SKMEL 5, SKMEL 28, WM266.4); Colon cancer cells (HCT116, BEneg, BE2, HT29, HT29oxaliR); Ovarian cancer cells (CH1, CH1doxR); Breast cancer cells (MB-231, MB-468, BT20, ZR751, MCF7, BT-474); nontumorigenic cells (HUVEC, MCF10a, PNT |
| 濃度 | ~10 μM | |
| 反応時間 | 4 days | |
| 実験の流れ | Antiproliferative effects are measured using the sulforhodamine B assay. HUVEC sensitivity is determined by an alkaline phosphatase method. | |
| 動物実験 | 動物モデル | HCT116 human colon cancer xenografts |
| 投薬量 | ~100 mg/kg | |
| 投与方法 | i.p. | |
|
| Antiviral activity of the HSP90 inhibitor VER-50589 against enterovirus 71 [ Antiviral Res, 2023, 211:105553] | PubMed: 36737007 |
| Evolution of kinase polypharmacology across HSP90 drug discovery [ Cell Chem Biol, 2021, S2451-9456(21)00221-X] | PubMed: 34077750 |
| A Repurposing Strategy for Hsp90 Inhibitors Demonstrates Their Potency against Filarial Nematodes [Gillan V, et al. PLoS Negl Trop Dis, 2014, 8(2):e2699] | PubMed: 24551261 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。